Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00310843 · ClinicalTrials.gov registry record

Case-Control Viramune (Nevirapine) Toxicogenomics Study

A clinical trial, sponsored by Boehringer Ingelheim.

Completed
Registry status
889
Enrollment target

NCT00310843 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 889 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00310843 has completed, sponsored by Boehringer Ingelheim.

COMPLETED
Registry status
889 participants
Enrollment target

Study Summary

Attempt to identify genetic polymorphisms in interrogated pathways which may be associated with symptomatic hepatotoxicity or severe cutaneous toxicity observed in case patients within the first 8 weeks of nevirapine therapy.

Interventions

  • DRUG Nevirapine

Trial Details

FieldValue
Enrollment Target 889 participants
Start Date 2006-02

Sponsor

Boehringer Ingelheim

515 total trials

What the Registry Record Tells You About NCT00310843

The ClinicalTrials.gov registry entry for NCT00310843 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 889 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Nevirapine is the first listed.

NCT00310843 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00310843 about?

NCT00310843 is a clinical study titled "Case-Control Viramune (Nevirapine) Toxicogenomics Study". Attempt to identify genetic polymorphisms in interrogated pathways which may be associated with symptomatic hepatotoxicity or severe cutaneous toxicity observed in case patients within the first 8 weeks of nevirapine therapy.

What is the current status of trial NCT00310843?

This trial is currently completed. The enrollment target is 889 participants. The study started on 2006-02.

What interventions are being tested in trial NCT00310843?

The interventions under investigation include: Nevirapine (DRUG).

Who is sponsoring clinical trial NCT00310843?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.